CAMBRIDGE, Mass., August 18, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that it has been nominated for the 2026 Prix Galien USA “Best Start-Up” Award in the Biotechnology category. This marks the second consecutive year Insilico has been recognized by Prix Galien USA, one of the life sciences industry’s most prestigious honors for scientific innovation.
The Galien Foundation was established in 1970 in honor of Galen, the father of medical science and modern pharmacology. Today, the Prix Galien, regarded as the Nobel Prize in biopharmaceutical research, spans more than 75 countries to honor the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation, with each candidate showing tremendous potential to improve human health. Insilico is honored to be nominated alongside fellow innovators including Mammoth Biosciences, SandboxAQ, Iambic Therapeutics, Hemab Therapeutics, Science Corporation, and many others advancing the future of human health.
The nomination follows a defining year for Insilico, marked by the advancement of its lead AI-discovered drug into Phase III clinical development, the company’s initial public offering on the Hong Kong Stock Exchange (HKEX: 3696), and significant growth in the commercial reach of its generative AI platform.
Since its 2025 nomination, Insilico has announced strategic out-licensing and drug-discovery agreements representing approximately $10 billion in aggregate potential value, including collaborations with Eli Lilly and Company valued at up to $2.75 billion and SK Biopharmaceuticals valued at up to $2.5 billion, as well as an agreement with China Medical System Holdings Limited. Together, these milestones reflect growing pharmaceutical adoption of Insilico’s AI-driven approach across internal drug development, partnered discovery, and platform-enabled research.
Central to this progress is rentosertib (ISM001-055), Insilico’s internally discovered and developed small-molecule TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). The program was created using Insilico’s commercially available Pharma.AI platform, integrating target identification through PandaOmics, generative chemistry through Chemistry42, and clinical development forecasting through InClinico.
In July 2026, Insilico initiated a global Phase III study of rentosertib, making it the first drug for which both the novel target and molecular structure were identified using generative AI to reach pivotal-stage clinical development.
“Being nominated for the Prix Galien USA Award for a second consecutive year is especially meaningful because of how much the company—and the field—has advanced since our first nomination,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “Over the past year, rentosertib has advanced into a Phase III clinical program, our internal pipeline has continued to mature, and we have expanded collaborations across the pharmaceutical industry. This recognition belongs to the scientists, clinicians, technologists, patients, and partners working with us to demonstrate that generative AI can contribute to the discovery and development of meaningful new medicines.”
Progress Since Insilico’s 2025 Nomination
First AI-discovered and AI-designed drug to enter Phase III: In July 2026, Insilico initiated a prospective, randomized, 52-week global Phase III study evaluating rentosertib in approximately 320 patients with IPF. The study follows Breakthrough Therapy Designation from China’s Center for Drug Evaluation.
Clinical proof of concept published in Nature Medicine: Results from a Phase IIa study showed dose-dependent changes in forced vital capacity (FVC). At 12 weeks, patients receiving the highest tested dose experienced a mean FVC increase of 98.4 mL, compared with a 20.3 mL decline among patients receiving placebo.
End-to-end discovery process published in Nature Biotechnology: The study detailed how Insilico used PandaOmics to identify TNIK as a fibrosis target and Chemistry42 to generate a novel small-molecule inhibitor, advancing the program from target nomination to a preclinical candidate in under 18 months.
Expanding clinical pipeline: Insilico’s platform has supported more than 33 pre clinical candidates across fibrosis, oncology, immunology, and other disease areas, with more than 13 pipelines receiving IND clearance.
Growing pharmaceutical adoption: Insilico is working with 13 of the world’s 20 largest pharmaceutical companies, providing external validation of its platform across target discovery, generative chemistry, and drug-development applications.
Successful public listing: Insilico completed its initial public offering on the Main Board of the Hong Kong Stock Exchange in December 2025, establishing a new foundation for the company’s continued global growth.
The 2026 Prix Galien USA Awards ceremony will take place on October 29, 2026, at the American Museum of Natural History in New York City.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, HKEX:3696.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.